SPD503 (1 mg)
SPD503-304
Phase 3 small_molecule completed
Quick answer
SPD503 (1 mg) for Attention Deficit Disorder With Hyperactivity is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Attention Deficit Disorder With Hyperactivity
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed